EP2968253A4 - METHOD FOR TREATING PEDIATRIC SOLID TUMORS - Google Patents

METHOD FOR TREATING PEDIATRIC SOLID TUMORS

Info

Publication number
EP2968253A4
EP2968253A4 EP14763546.0A EP14763546A EP2968253A4 EP 2968253 A4 EP2968253 A4 EP 2968253A4 EP 14763546 A EP14763546 A EP 14763546A EP 2968253 A4 EP2968253 A4 EP 2968253A4
Authority
EP
European Patent Office
Prior art keywords
methods
solid tumor
treating pediatric
pediatric solid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14763546.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2968253A1 (en
Inventor
Bouchra Benettaib
Ileana Elias
Markus Renschler
Neil P Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of EP2968253A1 publication Critical patent/EP2968253A1/en
Publication of EP2968253A4 publication Critical patent/EP2968253A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
EP14763546.0A 2013-03-13 2014-03-10 METHOD FOR TREATING PEDIATRIC SOLID TUMORS Withdrawn EP2968253A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780658P 2013-03-13 2013-03-13
US201361805817P 2013-03-27 2013-03-27
US201361829940P 2013-05-31 2013-05-31
US201361909868P 2013-11-27 2013-11-27
PCT/US2014/022541 WO2014143613A1 (en) 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor

Publications (2)

Publication Number Publication Date
EP2968253A1 EP2968253A1 (en) 2016-01-20
EP2968253A4 true EP2968253A4 (en) 2016-11-02

Family

ID=51537501

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14763546.0A Withdrawn EP2968253A4 (en) 2013-03-13 2014-03-10 METHOD FOR TREATING PEDIATRIC SOLID TUMORS

Country Status (12)

Country Link
US (1) US20160015817A1 (OSRAM)
EP (1) EP2968253A4 (OSRAM)
JP (3) JP6387389B2 (OSRAM)
KR (1) KR20150126671A (OSRAM)
CN (1) CN105209035A (OSRAM)
AU (2) AU2014228386B2 (OSRAM)
CA (1) CA2903470A1 (OSRAM)
HK (1) HK1219231A1 (OSRAM)
IL (1) IL240987A0 (OSRAM)
MX (1) MX2015011783A (OSRAM)
NZ (1) NZ630367A (OSRAM)
WO (1) WO2014143613A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI2117520T1 (sl) 2006-12-14 2019-01-31 Abraxis Bioscience, Llc Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan
ES2764100T3 (es) 2009-04-15 2020-06-02 Abraxis Bioscience Llc Composiciones de nanopartículas exentas de priones y métodos
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
BR112012024442A2 (pt) 2010-03-29 2017-03-21 Abraxis Bioscience Llc métodos de tratamento de câncer
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
CA2834040C (en) 2011-04-28 2020-01-14 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
HUE045661T2 (hu) 2011-12-14 2020-01-28 Abraxis Bioscience Llc Polimer segédanyagok alkalmazása részecskék liofilizálásához vagy fagyasztásához
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
LT3313401T (lt) 2015-06-29 2022-01-10 Abraxis Bioscience, Llc Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui
BR112020018910A2 (pt) 2018-03-20 2020-12-29 Abraxis Bioscience, Llc Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina
JP2022553426A (ja) 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CN1101700C (zh) * 1997-12-05 2003-02-19 上海众联生化技术开发有限公司 多肽口服液
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
CN1261161C (zh) * 2003-11-10 2006-06-28 钱汶光 复方干扰素诱生剂口含片
CN103285395A (zh) 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
CA2686736A1 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
WO2011063309A1 (en) * 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
CA2794147A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
MX343671B (es) * 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DESAI N ET AL: "Enhanced antitumor activity and safety of albumin-bound nab-docetaxel versus polysorbate 80-based docetaxel", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT; 18TH SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS; PRAGUE, CZECH REPUBLIC; NOVEMBER 07 -10, 2006, PERGAMON, OXFORD, GB, vol. 4, no. 12, 1 November 2006 (2006-11-01), pages 49, XP002699055, ISSN: 1359-6349, DOI: 2006 *
EVAN M. HERSH ET AL: "A phase 2 clinical trial of nab -paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma", CANCER., 1 January 2009 (2009-01-01), US, pages NA - NA, XP055262317, ISSN: 0008-543X, DOI: 10.1002/cncr.24720 *
HAWKINS M J ET AL: "Protein nanoparticles as drug carriers in clinical medicine", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 60, no. 8, 22 May 2008 (2008-05-22), pages 876 - 885, XP022624676, ISSN: 0169-409X, [retrieved on 20080207], DOI: 10.1016/J.ADDR.2007.08.044 *
IZBICKA ELZBIETA ET AL: "Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 26, no. 3A, 1 May 2006 (2006-05-01), pages 1983 - 1988, XP009157752, ISSN: 0250-7005 *
See also references of WO2014143613A1 *
SOUTHWELL T KAY ET AL: "Antitumor activity of Taxotere and paclitaxel against three human pediatric tumor xenograft models", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING; [CANCER RESEARCH; APRIL 2004, VOLUME 64, ISSUE 7, SUPPLEMENT], AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 44, 1 July 2003 (2003-07-01), pages 542, XP009191729, ISSN: 0197-016X *
ZHANG LIBO ET AL: "Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors", CLINICAL CANCER RESEARCH, vol. 19, no. 21, November 2013 (2013-11-01), pages 5972 - 5983, XP002762158 *

Also Published As

Publication number Publication date
MX2015011783A (es) 2015-12-01
JP2018062528A (ja) 2018-04-19
WO2014143613A1 (en) 2014-09-18
CN105209035A (zh) 2015-12-30
HK1219231A1 (zh) 2017-03-31
JP6387389B2 (ja) 2018-09-05
US20160015817A1 (en) 2016-01-21
NZ630367A (en) 2017-02-24
JP2019163334A (ja) 2019-09-26
JP2016512513A (ja) 2016-04-28
AU2014228386A1 (en) 2015-09-24
EP2968253A1 (en) 2016-01-20
AU2019201357A1 (en) 2019-03-21
CA2903470A1 (en) 2014-09-18
IL240987A0 (en) 2015-11-30
AU2014228386B2 (en) 2018-11-29
KR20150126671A (ko) 2015-11-12

Similar Documents

Publication Publication Date Title
EP2968253A4 (en) METHOD FOR TREATING PEDIATRIC SOLID TUMORS
EP2968191A4 (en) METHOD FOR THE TREATMENT OF BUBBLE CANCER
EP2943192A4 (en) METHOD FOR THE TREATMENT OF PANCREATIC CANCER
IL264901B (en) Administration of kynurenine depleting enzymes for tumor therapy
EP3288383A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2968208A4 (en) TREATMENT OF CATAPLEXIA
LT2885010T (lt) Tautopatijos gydymo būdai
EP2890806A4 (en) PROCESSING BIOMASS
MA43374A (fr) Méthodes de traitement de tumeurs malignes
EP2890720A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2920308A4 (en) CANCER TREATMENT
EP2968273A4 (en) METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES
PL3076967T3 (pl) Metody leczenia objawów rezydualnych schizofrenii
EP3011515A4 (en) LANGUAGE TRANSACTION PROCESSING
EP3035910A4 (en) COMPOSITIONS AND METHOD FOR TREATING HAIR
EP2892525A4 (en) METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES
LT3007726T (lt) Tautopatijos gydymo būdai
PT3626270T (pt) Tratamento de doenças cardiovasculares
EP2854839A4 (en) METHOD FOR THE TREATMENT OF CELIAC DISEASE
EP3389634A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2945639A4 (en) METHOD FOR THE TREATMENT OF HEART DISEASES
EP2635286A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2882429A4 (en) METHOD FOR TREATING NEURODEEGENERATIVE ILLNESSES
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
EP2817011A4 (en) CANCER TREATMENT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161006

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20160928BHEP

Ipc: A61K 9/51 20060101AFI20160928BHEP

Ipc: A61K 47/42 20060101ALI20160928BHEP

Ipc: A61K 31/337 20060101ALI20160928BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219231

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABRAXIS BIOSCIENCE, LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180924

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190916

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200128

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1219231

Country of ref document: HK